Impact of Pre-Hospital and Hospital Delays on Myocardial Infarction Outcomes
ConditionMyocardial Infarction (MI)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAl-Nahrain University
About this trial
The goal of this prospective observational study is to investigate the impact of pre-hospital and hospital delays on the outcomes of myocardial infarction (MI) patients admitted to Al-Kadhimiya Teaching Hospital, Baghdad.
The main questions it aims to answer are:
How do pre-hospital delays (e.g., patient transport and first medical contact) affect clinical outcomes such as mortality, complication rates, and recovery time in MI patients? What is the influence of hospital-related delays (e.g., time to intervention or reperfusion therapy) on the prognosis of MI patients?
Participants will:
Be monitored for the time elapsed from symptom onset to first medical contact and subsequent time intervals during hospital care.
Have their clinical outcomes, including in-hospital mortality, length of stay, and post-intervention complications, recorded and analyzed.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who provide informed consent (or a legal representative provides consent if the patient is unable to do so).
Patients who undergo reperfusion therapy, such as thrombolysis or percutaneous coronary intervention (PCI).
Patients admitted to Al-Kadhimiya Teaching Hospital within 12 hours of symptom onset.
Disqualifiers
Patients with non-acute myocardial infarction (e.g., stable angina, prior MI).
Patients with severe comorbidities (e.g., advanced cancer, end-stage renal disease) that may complicate outcome assessments or interfere with treatment protocols.
Patients who are transferred to another facility before reperfusion therapy is initiated.
Pregnant women or breastfeeding women.
Trial population
The study population will consist of adult patients aged 18 years and older who are diagnosed with acute myocardial infarction (MI), either STEMI or NSTEMI, confirmed by clinical symptoms, electrocardiogram (ECG), and elevated cardiac biomarkers (e.g., troponin). Participants will be admitted to Al-Kadhimiya Teaching Hospital within 12 hours of symptom onset and will undergo reperfusion therapy, such as thrombolysis or percutaneous coronary intervention (PCI).
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
In-hospital Mortality
percentage of patients who die during hospitalization following myocardial infarction.
Time frame
Up to discharge, an average of 7 daysSecondary outcomes
1
Time-to-Reperfusion Therapy
The time (in minutes) from symptom onset to the initiation of reperfusion therapy (e.g., thrombolysis or percutaneous coronary intervention).
Time frame
Pre-Hospital Delay: Average of 4 hours from symptom onset to first medical contact. Hospital Delay: Average of 2 hours from hospital admission to the initiation of reperfusion therapy.2
Length of Hospital Stay
The total duration of a patient's stay in the hospital, measured from the date of admission to the date of discharge.
Time frame
Up to discharge, an average of 7 days3
Major Adverse Cardiac Events (MACE)
Includes recurrent myocardial infarction, heart failure, and arrhythmias occurring during hospitalization.
Time frame
Up to discharge, an average of 7 days4
Complication Rate
The proportion of patients developing complications related to delays in treatment (e.g., cardiogenic shock, ventricular rupture).
Time frame
Up to discharge, an average of 7 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov